High-dose chemotherapy for Hodgkin's disease and its risks
Author Information
Author(s): Harrison C N, Gregory W, Hudson G Vaughan, Devereux S, Goldstone A H, Hancock B, Winfield D, MacMillan A K, Hoskin P, Newland A C, Milligan D, Linch D C
Primary Institution: University College Medical School, London, UK
Hypothesis
Is high-dose BEAM chemotherapy with autologous stem cell transplantation associated with an increased risk of secondary MDS/AML in Hodgkin's disease patients?
Conclusion
The study found no significant evidence that high-dose BEAM therapy and autologous transplantation increase the risk of MDS/AML in Hodgkin's disease patients.
Supporting Evidence
- The study analyzed data from 4576 patients with Hodgkin's disease.
- 595 of these patients received high-dose BEAM chemotherapy and autologous transplantation.
- Statistical analysis showed that prior therapy significantly influenced the risk of developing MDS/AML.
- The relative risk associated with transplantation was found to be 1.83 after adjusting for other factors.
Takeaway
Doctors found that giving high-dose chemotherapy to treat Hodgkin's disease doesn't seem to cause a higher chance of getting a serious blood disease later.
Methodology
A retrospective comparative study analyzing data from Hodgkin's disease patients, using statistical models to assess risks.
Participant Demographics
4576 patients with Hodgkin's disease, including 595 who received a transplant.
Statistical Information
P-Value
P < 0.0001; P = 0.0009; P = 0.001; P = 0.25
Confidence Interval
95% CI 1.49–2.71; 95% CI 1.64–7.95; 95% CI 1.96–10.44; 95% CI 0.66–5.11
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website